These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 29630956)

  • 1. Mirabegron 25 mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction.
    Liao CH; Kuo HC
    Urology; 2018 Jul; 117():115-119. PubMed ID: 29630956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.
    Nitti VW; Rosenberg S; Mitcheson DH; He W; Fakhoury A; Martin NE
    J Urol; 2013 Oct; 190(4):1320-7. PubMed ID: 23727415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
    Blais AS; Nadeau G; Moore K; Genois L; Bolduc S
    Eur Urol; 2016 Jul; 70(1):9-13. PubMed ID: 26876327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
    Herschorn S; Barkin J; Castro-Diaz D; Frankel JM; Espuna-Pons M; Gousse AE; Stölzel M; Martin N; Gunther A; Van Kerrebroeck P
    Urology; 2013 Aug; 82(2):313-20. PubMed ID: 23769122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet.
    Herschorn S; Staskin D; Schermer CR; Kristy RM; Wagg A
    Drugs Aging; 2020 Sep; 37(9):665-676. PubMed ID: 32725584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy.
    Shin JH; Kim A; Choo MS
    Investig Clin Urol; 2017 Jul; 58(4):261-266. PubMed ID: 28681036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).
    Nakagomi H; Mitsui T; Shimura H; Ihara T; Kira S; Sawada N; Takeda M
    BMC Urol; 2022 Mar; 22(1):40. PubMed ID: 35313873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.
    Otsuki H; Kosaka T; Nakamura K; Mishima J; Kuwahara Y; Tsukamoto T
    Int Urol Nephrol; 2013 Feb; 45(1):53-60. PubMed ID: 23212147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
    Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
    Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mirabegron (Myrbetriq) for overactive bladder.
    Med Lett Drugs Ther; 2013 Feb; 55(1410):13-5. PubMed ID: 23459457
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study.
    Yoshida M; Nozawa Y; Kato D; Tabuchi H; Kuroishi K
    Low Urin Tract Symptoms; 2019 Jan; 11(1):30-38. PubMed ID: 28901041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
    MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Grise P; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Hemsted C; Nazir J; Hakimi Z; Drake MJ;
    J Urol; 2016 Sep; 196(3):809-18. PubMed ID: 27063854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A drug safety evaluation of mirabegron in the management of overactive bladder.
    Robinson D; Thiagamoorthy G; Cardozo L
    Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).
    Wagg A; Staskin D; Engel E; Herschorn S; Kristy RM; Schermer CR
    Eur Urol; 2020 Feb; 77(2):211-220. PubMed ID: 31733990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes with the β
    Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
    Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.